| 12.06 09:07 | dpa-AFX: *EVOTEC TESTEN MIT +3,7% DIE 21-TAGE-LINIE - HOCH SEIT ENDE MAI |
| 12.06 07:47 | Evotec erhält Forschungszahlung von 20 Mio USD von Myers Squibb |
| 12.06 07:43 | dpa-AFX: *EVOTEC BEI L&S +2,0% - FORTSCHRITTE MIT BRISTOL-MYERS-SQUIBB LÖSEN ZAHLUNG AUS |
| 05.06 13:43 | dpa-AFX: I-Mab Inks Partnership With Bristol Myers Squibb To Evaluate Givastomig In Combination Study |
| 03.06 18:26 | dpa-AFX: Bristol Myers' 3 Breyanzi Trials Show Consistent Benefit Across B-Cell Malignancies |
| 03.06 16:24 | dpa-AFX: *BRISTOL MYERS SQUIBB'S BREYANZI DATA SHOWS SIGNIFICANT BENEFITS ACROSS DIVERSE B-CELL MALIGNANCIES |
| 22.05 09:32 | dpa-AFX: *NEOPHORE CLOSES OVERSUBSCRIBED SERIES B EXTENSION ROUND WITH ADDITIONAL FUNDING FROM BRISTOL MYERS SQUIBB |
| 21.05 13:19 | dpa-AFX: *HALOZYME: BRISTOL MYERS SQUIBB GETS UPDATED ACTION DATE OF DEC. 29 FOR SUBCUTANEOUS NIVOLUMAB CO-FORMULATED WITH ENHANZE |
| 06.05 14:10 | dpa-AFX: Bristol Myers Says Type II Variation Application For Opdivo + Yervoy Granted EMA Validation |
| 06.05 13:56 | dpa-AFX: *BMY :OPDIVO + YERVOY GRANTED EMA VALIDATION FOR FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER |
| 30.04 19:48 | dpa-AFX: Biotech Stocks Facing FDA Decision In May 2024 |
| 29.04 12:26 | dpa-AFX: Repertoire Immune Medicines In Strategic Partnership With Bristol Myers Squibb |
| 29.04 12:02 | dpa-AFX: *REPERTOIRE® IMMUNE MEDICINES, BRISTOL MYERS SQUIBB ENTER STRATEGIC COLLABORATION TO DEVELOP TOLERIZING VACCINES |
| 26.04 15:38 | dpa-AFX: Bristol Myers: CHMP Recommends Approval Of Opdivo In Combination With Cisplatin And Gemcitabine |
| 26.04 15:09 | dpa-AFX: *CHMP BACKS BRISTOL-MYERS' OPDIVO COMBO FOR UROTHELIAL CARCINOMA |
| 26.04 06:00 | dpa-AFX: *RPT/JEFFERIES CUTS BRISTOL-MYERS SQUIBB PRICE TARGET TO 54 (56) USD - 'HOLD' |
| 26.04 06:00 | dpa-AFX: *WDH/JEFFERIES SENKT ZIEL FÜR BRISTOL-MYERS SQUIBB AUF 54 (56) USD - 'HOLD' |
| 25.04 18:29 | dpa-AFX: *JEFFERIES CUTS BRISTOL-MYERS SQUIBB PRICE TARGET TO 54 (56) USD - 'HOLD' |
| 25.04 18:29 | dpa-AFX: *JEFFERIES SENKT ZIEL FÜR BRISTOL-MYERS SQUIBB AUF 54 (56) USD - 'HOLD' |
| 25.04 13:41 | dpa-AFX: Bristol Myers Squibb Posts Loss In Q1; Updates 2024 Non-GAAP EPS Guidance |
|
|
